In our examined TFH+ PTCLs, large cell PTCL-TFH patients had a similar incidence of RHOA G17V mutation (36%) to those with AITL (42%), but showed higher expressions of CD25 (IL2R), CD30, CMYC, and CMYC mRNA, than small cell PTCL-TFH patients and AITL (p < 0.05 or p < 0.01, respectively). This evidence concerns the gene IL2RA and angioimmunoblastic T-cell lymphoma.